Introduction Since calcitonin gene-related peptide (CGRP) plays an important role in the
pathophysiology of migraine via the activation of the trigeminovascular system, the newest …

Introduction Migraine is a leading cause of years lived with disability and preventive
strategies represent a mainstay to reduce health-related disability and improve quality of life …

Migraine is ranked as a leading cause of years lived with disability among all neurological
disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling …

Migraine is the most prevalent neurological disorder worldwide and it has immense
socioeconomic impact. Currently, preventative treatment options for migraine include drugs …

Background Several drugs are available for the preventive treatment of both episodic and
chronic migraine. The choice of which therapy to initiate first, second, or third is not …

Calcitonin gene‐related peptide (CGRP) is expressed throughout the CNS and peripheral
nervous system, consistent with control of vasodilatation, nociception, motor function …

Migraine is a highly prevalent, complex neurological disorder. The burden of disease and
the direct/indirect annual costs are enormous. Thus far, treatment options have been …

Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as
antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies …

Background: Monoclonal antibodies that target calcitonin gene-related peptide or the
canonical calcitonin gene-related peptide receptor have emerged as effective and well …

Purpose of Review CGRP is a key neuropeptide in migraine pathophysiology. The blockade
of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the …